Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Melanoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1PD-L1-selected Solid Tumors 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

Sunitinib 64Nivolumab 54Sorafenib 38Bevacizumab 35Axitinib 35pembrolizumab 34Everolimus 30cabozantinib 29pazopanib 26aldesleukin 26Ipilimumab 23Interleukin-2 19Specimen Handling 17Magnetic Resonance Spectroscopy 17Gemcitabine 17lenvatinib 16Interferon-alpha 15Interferon alpha-2 13Radiosurgery 12Cyclophosphamide 12fludarabine phosphate 11atezolizumab 10durvalumab 8Introns 8Erlotinib Hydrochloride 8Biopsy 8temsirolimus 7avelumab 7Radiotherapy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Renal Cell × Tiragolumab × Clear all
NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Active not recruiting
199 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡